ABL Bio is focused on developing immuno-oncology drugs and neurodegenerative disorder treatments. Their pipeline includes ABL001, an anti-VEGF/DLL4 BsAb for solid cancer, and ABL301, a treatment for Parkinson’s Disease.
Latest News
No feed items found.
